.Noso S1, Park C, Babaya N, Hiromine Y, Harada T, Ito H, Taketomo Y, Kanto K, Oiso N, Kawada A, Suzuki T, Kawabata Y, Ikegami H. J Clin Endocrinol Metab. 2015 May;100(5):1976-83 Although alopecia areata (AA) is one of the most frequent organ-specific autoimmune diseases, the association of AA with other autoimmune diseases and the […]

Induction of painless thyroiditis in patients receiving programmed death 1 receptor immunotherapy for metastatic malignancies Orlov S1, Salari F, Kashat L, Walfish PG. . J Clin Endocrinol Metab. 2015 May;100(5):1738-41 Immunotherapies against immune checkpoints that inhibit T cell activation [cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed cell death 1 (PD-1)] are emerging and promising […]

Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate-risk papillary thyroid cancer.Ruel E1, Thomas S, Dinan M, Perkins JM, Roman SA, Sosa JA. J Clin Endocrinol Metab. 2015 Apr;100(4):1529-36 Papillary thyroid cancer (PTC) is the most common endocrine malignancy. The long-term prognosis is generally excellent. Due to a paucity of data, […]

Prophylactic central compartment lymph node dissection in papillary thyroid carcinoma: clinical implications derived from the first prospective randomized controlled single institution study.Viola D1, Materazzi G, Valerio L, Molinaro E, Agate L, Faviana P, Seccia V, Sensi E, Romei C, Piaggi P, Torregrossa L, Sellari-Franceschini S, Basolo F, Vitti P, Elisei R, Miccoli P. J Clin […]